Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Recommendation of “Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received a consensus recommendation of “Buy” from the seven research firms that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $37.43.

A number of brokerages recently commented on DYN. Stifel Nicolaus lifted their target price on shares of Dyne Therapeutics from $35.00 to $41.00 and gave the stock a “buy” rating in a research report on Wednesday, March 6th. Piper Sandler upped their target price on Dyne Therapeutics from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Raymond James upped their price target on Dyne Therapeutics from $27.00 to $56.00 and gave the stock a “strong-buy” rating in a research note on Thursday, January 4th. Oppenheimer reissued an “outperform” rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research report on Tuesday, March 26th. Finally, HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, March 6th.

Dyne Therapeutics Trading Up 4.4 %

Shares of NASDAQ:DYN opened at $24.73 on Wednesday. Dyne Therapeutics has a 1-year low of $6.40 and a 1-year high of $30.27. The stock has a market cap of $2.13 billion, a PE ratio of -6.28 and a beta of 0.95. The stock’s fifty day simple moving average is $26.10 and its two-hundred day simple moving average is $17.94.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.17). On average, sell-side analysts forecast that Dyne Therapeutics will post -3.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Wildon Farwell sold 5,493 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $25.07, for a total transaction of $137,709.51. Following the transaction, the insider now directly owns 163,503 shares of the company’s stock, valued at $4,099,020.21. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other Dyne Therapeutics news, insider Wildon Farwell sold 5,493 shares of Dyne Therapeutics stock in a transaction on Monday, February 12th. The shares were sold at an average price of $25.07, for a total value of $137,709.51. Following the transaction, the insider now directly owns 163,503 shares of the company’s stock, valued at $4,099,020.21. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Susanna Gatti High sold 1,591 shares of the stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $25.85, for a total value of $41,127.35. Following the completion of the sale, the chief operating officer now owns 186,291 shares of the company’s stock, valued at $4,815,622.35. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,875,432 shares of company stock worth $44,368,530. 20.77% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Fcpm Iii Services B.V. purchased a new position in Dyne Therapeutics during the fourth quarter valued at $81,543,000. Braidwell LP boosted its holdings in Dyne Therapeutics by 32.2% in the 3rd quarter. Braidwell LP now owns 1,821,972 shares of the company’s stock worth $16,325,000 after buying an additional 444,100 shares during the last quarter. Vivo Capital LLC increased its stake in Dyne Therapeutics by 58.0% during the 1st quarter. Vivo Capital LLC now owns 1,635,136 shares of the company’s stock worth $46,422,000 after buying an additional 600,000 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of Dyne Therapeutics by 31.6% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company’s stock valued at $10,752,000 after acquiring an additional 288,000 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. purchased a new position in shares of Dyne Therapeutics in the fourth quarter valued at approximately $15,758,000. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.